Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270782 | 1.00 | PDE4B (0.50) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4282199 | 0.94 | PDE4B (0.49) | PDE4BGPR119PDE4APDE4CPDE4D | |
| SCHEMBL4270770 | 0.89 | PDE4B (0.50) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4270778 | 0.89 | PDE4B (0.50) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3164585 | 0.85 | GPR119 (0.51) | PDE4BGPR119PDE4APDE4CPDE4D | |
| SCHEMBL4282196 | 0.82 | GPR119 (0.50) | PDE4BGPR119PDE4APDE4CPDE4D | |
| SCHEMBL20179924 | 0.79 | GPR119 (0.58) | PIK3CDGPR119USP30KMT2ANPBWR1 | |
| SCHEMBL4277747 | 0.79 | GPR119 (0.49) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4277754 | 0.79 | GPR119 (0.49) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5362711 | 0.78 | PDE4B (0.48) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1644334-B1 | ANTITHROMBOTIC ETHERS | LILLY CO ELI (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1644334-A1 | ANTITHROMBOTIC ETHERS | Eli Lilly and Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108677-A1 | ANTITHROMBOTIC ETHERS | ELI LILLY AND COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | PDE4B 2222/4885PIK3CD 2638/4885PIK3CA 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.